DK1196442T3 - VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser - Google Patents

VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser

Info

Publication number
DK1196442T3
DK1196442T3 DK00947543T DK00947543T DK1196442T3 DK 1196442 T3 DK1196442 T3 DK 1196442T3 DK 00947543 T DK00947543 T DK 00947543T DK 00947543 T DK00947543 T DK 00947543T DK 1196442 T3 DK1196442 T3 DK 1196442T3
Authority
DK
Denmark
Prior art keywords
vgf
methods
polypeptides
treatment
related disorders
Prior art date
Application number
DK00947543T
Other languages
Danish (da)
English (en)
Inventor
Hai Yan
Thomas C Boone
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1196442T3 publication Critical patent/DK1196442T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
DK00947543T 1999-07-21 2000-07-19 VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser DK1196442T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14479799P 1999-07-21 1999-07-21

Publications (1)

Publication Number Publication Date
DK1196442T3 true DK1196442T3 (da) 2006-05-08

Family

ID=22510177

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00947543T DK1196442T3 (da) 1999-07-21 2000-07-19 VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser

Country Status (10)

Country Link
EP (1) EP1196442B1 (fr)
JP (2) JP2003505471A (fr)
AT (1) ATE313561T1 (fr)
AU (1) AU783199B2 (fr)
CA (1) CA2380037A1 (fr)
DE (1) DE60024997T2 (fr)
DK (1) DK1196442T3 (fr)
ES (1) ES2255502T3 (fr)
MX (1) MXPA02000680A (fr)
WO (1) WO2001007477A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029840A1 (fr) * 2004-09-14 2006-03-23 Geneprot Inc. Especes de polypeptides utiles dans le traitement de troubles neurologiques
GB0502979D0 (en) * 2005-02-14 2005-03-16 Univ Cambridge Tech Biomarkers and uses thereof
WO2006118313A1 (fr) * 2005-04-27 2006-11-09 Takeda Pharmaceutical Company Limited Nouveau polypeptide et utilisation
US20100248255A1 (en) * 2005-07-29 2010-09-30 Kyowa Hakko Kogyo Co., Ltd Novel peptides
JPWO2007105442A1 (ja) * 2006-02-22 2009-07-30 協和発酵キリン株式会社 摂食障害または摂水障害の治療薬
WO2008090678A1 (fr) * 2007-01-25 2008-07-31 Kyowa Hakko Kirin Co., Ltd. Nouveau peptide
WO2011005488A1 (fr) 2009-06-22 2011-01-13 Amgen Inc. Repliement de protéines au moyen d’un état redox chimiquement régulé
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
EP2380920A1 (fr) * 2010-04-22 2011-10-26 QGel SA Formulation de précurseur d'hydrogel et son procédé de fabrication
WO2012091041A1 (fr) * 2010-12-28 2012-07-05 協和発酵キリン株式会社 Promoteur de sécrétion d'insuline
KR102505358B1 (ko) 2020-01-06 2023-03-06 재단법인 아산사회복지재단 Vgf 유래 펩티드를 포함하는 골 질환의 예방 또는 치료용 조성물
WO2021141355A1 (fr) * 2020-01-06 2021-07-15 재단법인 아산사회복지재단 Composition comprenant un peptide dérivé de vgf destiné à la prévention ou au traitement de maladie osseuse

Also Published As

Publication number Publication date
DE60024997D1 (de) 2006-01-26
EP1196442B1 (fr) 2005-12-21
ATE313561T1 (de) 2006-01-15
WO2001007477A1 (fr) 2001-02-01
AU6112700A (en) 2001-02-13
CA2380037A1 (fr) 2001-02-01
EP1196442A1 (fr) 2002-04-17
MXPA02000680A (es) 2002-07-02
DE60024997T2 (de) 2006-08-24
ES2255502T3 (es) 2006-07-01
JP2003505471A (ja) 2003-02-12
JP2006176528A (ja) 2006-07-06
AU783199B2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
MXPA03002413A (es) Moleculas tipo b7 y uso de las mismas.
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
ATE413386T1 (de) Ppar-gamma modulatoren
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2005046603A3 (fr) Composes pyridiniques
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
AU2386201A (en) Substituted sapogenins and their use
DK2077279T3 (da) Tymiske stromale lymfopoietinreceptormolekyler og anvendelser heraf
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
WO2001068854A3 (fr) Molecules s'apparentant au facteur de croissance des fibroblastes et leurs utilisations
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
TR199902257T2 (xx) Tetrahidropirido bile�ikleri
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
DK1532131T3 (da) Motilid-forbindelser
DK1220852T3 (da) Substituerede diazepaner
WO2001042474A3 (fr) Molecules de type interferon et utilisations
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser